Extended Data Fig. 8: Proteasome inhibition counteracts digoxin effect on REV-ERBα levels.
Quantification of data appears in Fig. 5. REV-ERBα protein level in synchronized AC16 cells (a) treated with either vehicle, digoxin (0.5 µM) and/or clasto-lactacystin β-lactone (10 µM, proteasomal Inhibitor), (b) treated with either vehicle, digoxin (0.5 µM) and/or bortezomib (200 nM, PSMB5 inhibitor), in synchronized U2OS cells treated (c) with either vehicle, digoxin (0.5 µM) and/or bortezomib (200 nM, PSMB5 inhibitor)in synchronized AC16 cells (d) in synchronized AC16 cells transfected with Flag-Rev-ERBα or Flag-Rev-ERBα-H602F then treated with vehicle or digoxin (0.5 µM). HSP90α was used as a protein loading control.
